Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms

2020 Year in Review - Neuroendocrine Tumors - Neuroendocrine Tumors

Results of a retrospective analysis showed that checkpoint inhibitors as monotherapy had limited clinical benefit in patients with grade 3 neuroendocrine tumors (NETs) or neuroendocrine carcinomas (NECs), and modest benefit when combined with another checkpoint inhibitor or chemotherapy.

To further characterize the treatment outcomes and responses achieved with immune checkpoint inhibitors in high-grade neuroendocrine neoplasms (NENs), a retrospective cohort study was conducted in patients with grade 3 NETs or NECs, which are distinct NENs; the results of this study were reported at the 2020 North American Neuroendocrine Tumor Society Annual Symposium.

The study included all patients aged ≥18 years, with a diagnosis of NEN at the Mayo Clinic between 2000 and 2020, who were treated with checkpoint inhibitors as monotherapy or combined with other checkpoint inhibitors or cytotoxic chemotherapy. Retrospective tumor response assessment and imaging interpretation was conducted to confirm results. Primary end points were objective response rate (ORR), progression-free survival (PFS), overall survival, and disease control rate.

A total of 46 eligible patients with NEC were identified; of these, 11 were treated with checkpoint inhibitor monotherapy (pembrolizumab, nivolumab, or atezolizumab), 15 patients were treated with dual checkpoint inhibitors (nivolumab + ipilimumab), and 20 patients received checkpoint inhibitors + chemotherapy (platinum/etoposide). Five patients with grade 3 NETs who had received checkpoint inhibitor monotherapy were also identified.

Among patients who received checkpoint inhibitor monotherapy, the median PFS was 2.1 months (range, 0.5-4.6 months; ORR, 0%), which was similar to the grade 3 NET cohort (median PFS, 2.9 months; ORR, 0%). Patients with NECs who received checkpoint inhibitors plus chemotherapy achieved an ORR of 36% and a median PFS of 4.2 months (1.6 months-not reached [NR]), whereas those who had received dual checkpoint inhibitor therapy achieved an ORR of 11% and a median PFS of 3.5 (1.4-NR) months.

Based on the results of this retrospective analysis, checkpoint inhibitors were associated with limited clinical benefit as monotherapy in patients with grade 3 NETs or NECs, with modest benefit when combined with another checkpoint inhibitor or chemotherapy.

Source: Gile J, et al. North American Neuroendocrine Tumor Society 2020 Annual Symposium; October 1-3, 2020. Abstract C6.

Related Items
Neuroendocrine Year in Review Introduction
2020 Year in Review - Neuroendocrine Tumors published on January 25, 2021 in Neuroendocrine Tumors
CLARINET FORTE Study Results of Lanreotide Autogel in Progressive Pancreatic or Midgut NETs
2020 Year in Review - Neuroendocrine Tumors published on January 25, 2021 in Neuroendocrine Tumors
Avelumab in Unresectable/Metastatic, Progressive Neuroendocrine Neoplasms
2020 Year in Review - Neuroendocrine Tumors published on January 7, 2021 in Neuroendocrine Tumors
Phase 2 NICE-NEC Study of First-Line Platinum-Doublet Chemotherapy + Nivolumab in Unresectable Locally Advanced or Metastatic Grade 3 NENs
2020 Year in Review - Neuroendocrine Tumors published on January 7, 2021 in Neuroendocrine Tumors
Irinotecan + Cisplatin versus Etoposide + Cisplatin for High-Grade Neuroendocrine Carcinoma of the Lung
2020 Year in Review - Neuroendocrine Tumors published on January 7, 2021 in Neuroendocrine Tumors
Temozolomide Alone or Combined with Capecitabine in Metastatic Neuroendocrine Neoplasia
2020 Year in Review - Neuroendocrine Tumors published on January 7, 2021 in Neuroendocrine Tumors
Toxicity Profile of Capecitabine/Temozolomide in NETs
2020 Year in Review - Neuroendocrine Tumors published on January 7, 2021 in Neuroendocrine Tumors
Cabozantinib in High-Grade Neuroendocrine Neoplasms
2020 Year in Review - Neuroendocrine Tumors published on January 7, 2021 in Neuroendocrine Tumors
Efficacy of FOLFOX with or without Bevacizumab in Patients with Aggressive Pancreatic NETs
2020 Year in Review - Neuroendocrine Tumors published on January 7, 2021 in Neuroendocrine Tumors
Patient-Reported Activity Impairment, Work Productivity Loss, and Carcinoid Syndrome from the XERMELO Patient Registry
2020 Year in Review - Neuroendocrine Tumors published on January 7, 2021 in Neuroendocrine Tumors
Last modified: July 22, 2021